FDA grants Priority Review to Roche ’s baloxavir marboxil for the treatment of influenza

Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in patients 12 years and older.

https://www.roche.com/investors/updates/inv-update-2018-06-26.htm

Source: Roche Investor Update - June 26, 2018 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Grants | Influenza | New Drug Applications | Pharmaceuticals